VIR Share Price Performance
US$5.80
-1.79 (-23.58%)
67.1% undervalued intrinsic discount
US$17.63
Fair Value
Price US$5.80
AnalystConsensusTarget US$17.63
Fair ValueUS$17.63
Share PriceUS$5.80
67.1% undervalued intrinsic discount
Vir Biotechnology, Inc. Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 12 Fair Values set on narratives written by author
VIR Community Narratives
AN
Fair Value US$17.63 65.7% undervalued intrinsic discount
Strong Clinical Advances In Oncology And Hepatitis Delta Will Secure Future Success
0users have liked this narrative
0users have commented on this narrative
12users have followed this narrative
Vir Biotechnology, Inc. Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -3.96
- Gross Margin
- -2,461.06%
- Net Profit Margin
- -2,895.94%
- Debt/Equity Ratio
- 0%
Vir Biotechnology, Inc. Competitors
Snowflake Analysis
About VIR
- Founded
- 2016
- Employees
- 408
- CEO
- WebsiteView website
Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors.The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). It has grant agreements with Gates Foundation; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.
Market Insight
Q4 2025 is off to a flying start with record highs being printed left, right, and center. US and Japanese stocks made fresh new highs, while the gold price powered through $4,000 for the first time, and Bitcoin crossed the $126k level. Is this all a case of USD weakness, irrational exuberance, or solid fundamentals? This week, we are reviewing Q3 market performance, Q2 earnings season, and the outlook heading into the end of 2025…
Continue reading
U.S. Market Performance
- 7 Days: -2.8%
- 3 Months: 5.3%
- 1 Year: 13.4%
- Year to Date: 11.7%
Over the last 7 days, the market has dropped 2.8%, driven by a decline of 2.5% in the Information Technology sector. As for the longer term, the market has actually risen by 13% in the last year. As for the next few years, earnings are expected to grow by 15% per annum. Market details ›